Cannabis Report
Home > Boards > US Listed > Biotechs >

GT Biopharma Inc. (GTBP)

GTBP RSS Feed
Add GTBP Price Alert      Hide Sticky   Hide Intro
Moderator: 236T568, CashBowski, Duke_DD_em, cleantrader, BlissTaxi, GemsBond
Search This Board: 
Last Post: 9/17/2018 10:56:30 AM - Followers: 178 - Board type: Free - Posts Today: 0

OTCQB: GTBP







The Scourge of Cancer

Cancer is the second leading cause of death globally, and responsible for 8.8 million deaths annually.  The economic impact of cancer is increasing. The total annual economic cost of cancer in 2015 was estimated at approximately US$ 2.5 trillion.  Immuno Oncology sits on the leading edge of cancer treatment and research.  In terms of effectiveness it promises to drastically outpace all previous forms of conventional cancer therapy.  Some estimate the Immuno Oncology market at $US 40 Billon and growing.



What is Immuno Oncology?

Immuno Oncology is treatment that recruits and supercharges a person's own immune system components to fight cancer. This can take various forms: the immune system can be stimulated to work harder or smarter in attacking cancer cells, immune system components can be supplied such as man-made immune proteins that attack cancer cells in a targeted way, immune system cells can be "programmed" to only attack very specific cancer cells or even to deliver a "payload" of compounds poisonous to cancer directly and only to the malignant cells. 
 

   




Immuno Oncology Goes Beyond Drawbacks of Conventional Chemotherapy
Conventional chemotherapy poisons the patient's body with the aim of getting the cancer too. Its like spraying a powerful herbicide on your rose garden to get rid of the dandelions. Yes, the weeds will die but the roses will suffer too.

With Immuno Oncology, the cure is not worse than the disease. Many of the harsh and debilitating side effects of chemotherapy are avoided because the agents that kill the cancer are components of the human immune system itself, rather than poison, and the therapy can be precisely targeted to only attack the cancerous cells.  It is truly the next evolutionary leap in cancer treatment.   




GT Biopharma Portfolio



GTBP Therapy Pipeline Highlights

OXS-1550: Treating Lymphoma and Leukemia
When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550, and are killed due to the action of drug’s cytotoxic diphtheria toxin payload.  OXS-1550 has demonstrated success in a Phase 1 human clinical trial in patients with relapsed/refractory B-cell lymphoma or leukemia.

The initial phase 1 study enrolled 25 patients (who) received at least a single course of therapy. The treatment at the higher doses produced objective tumor responses with one patient in continuous partial remission and the second in complete remission. Data from ongoing phase 2 expected in 2H ‘18.

OXS-3550: Treating Leukemia
The OXS-3550 IND will focus on AML, the most common form of adult leukemia with 21,000 new cases expected in 2017 alone (American Cancer Society). These patients will require frontline therapy, usually chemotherapy including cytarabine and an anthracycline, a therapy that has not changed in over 40 years.

OXS-1615 AND OXS-C3550: Treating Solid Tumors
This TetraKE is designed to kill not only the heterogeneous population of cancer cells found in solid tumors but also kill the cancer stem cells that are typically responsible for recurrences.



Other Offerings: Central Nervous System Therapies

GTP-011: Motion Sickness Treatment

GTP-011 is a 72-hour patch for which a patent application has been filed by GTP for the prevention of motion sickness, a well-known syndrome that typically involves nausea and vomiting in otherwise healthy people and that occurs upon exposure to certain types of motion.

PainBrake: Treating Neuropathic Pain 
PainBrake® is a new patented formulation of carbamazepine (Tegretol®) that enables accurate dose fractionation for the treatment of neuropathic pain.  An NIH-supported study estimated that almost 16 million Americans suffer from chronic neuropathic pain. Current drugs provide a useful degree of pain relief in only about half the patients. 

GTP-004: Treating Myasthenia Gravis
GTP-004 is a fixed-dose combination tablet for the treatment of myasthenia gravis. Myasthenia gravis is a chronic autoimmune disease of the neuromuscular junction characterized by muscle weakness. The prevalence of the disease in the United States is estimated at 14 to 20 per 100,000 population, approximately 36,000 to 60,000 cases in the U.S. 

 


GT Biopharma Executive Team: A Who's Who Of The Biotech Sector

"Look at Where Deutsche Bank’s Shawn Cross, Pfizer’s Dr. Raymond Urbanski, Chase Pharmaceutical’s Dr. Kathleen Clarence-Smith, and Barker Davis Founder Geoffrey Davis are making their bets.  Some of the biotech sector’s most affluent and influential individuals are making a move... to GT Biopharma Inc. (GTBP). This up-and-coming biotech company has a therapy pipeline that has attracted some of the industry’s most experienced leaders."




 



Company Website

GTBP Investor's Overview

GTBP News



Cannabis Report
GTBP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GTBP News: Current Report Filing (8-k) 09/07/2018 05:06:03 PM
GTBP News: Quarterly Report (10-q) 08/14/2018 05:15:43 PM
GTBP News: Current Report Filing (8-k) 08/03/2018 09:31:45 AM
GTBP News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 08/03/2018 09:18:52 AM
GTBP News: Current Report Filing (8-k) 07/05/2018 06:03:10 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#16460  Sticky Note GTBP CEO Shawn Cross ABRUPTLY resigns as CEO 236T568 07/25/18 01:52:51 PM
#16435  Sticky Note GT Biopharma Announces the Addition of Dr. John cleantrader 07/25/18 10:45:50 AM
#12195  Sticky Note DUKE's MASSIVE DD POST ON $GTBP or HOW Duke_DD_em 05/04/18 08:56:30 PM
#11766  Sticky Note $GTBP Exec Team Stacked with Superstars. The Duke_DD_em 05/01/18 02:58:41 PM
#9588  Sticky Note The topic of this board is OXIS. The CashBowski 03/31/17 11:03:34 AM
#17801   GTBP Charts conix 09/17/18 10:56:29 AM
#17800   the key here is 236T568 09/14/18 05:21:23 PM
#17799   Damn I left out a cool mill in CashBowski 09/14/18 03:02:13 PM
#17798   $1.80 - lowest price in 2 months! 236T568 09/12/18 12:47:12 PM
#17797   Its now at about $2.6 million cash for 236T568 09/10/18 05:22:24 PM
#17796   Spending well over a million $ in a CashBowski 09/10/18 09:14:43 AM
#17795   All stocks need stock awareness, Looking for another simmons420 09/09/18 09:50:42 PM
#17794   Yeah, that headline is a little deceptive, but CashBowski 09/06/18 02:57:26 PM
#17793   Looking good here, let's see if we can simmons420 09/06/18 12:15:59 PM
#17791   Ha! and just when you thought that GTBP 236T568 08/30/18 11:45:45 AM
#17790   GT Biopharma's Chairman and Chief Executive Officer Raymond Gumby525 08/30/18 08:57:55 AM
#17789   Easy enough to check. I would pay particular simon wagstaff 08/29/18 01:25:00 PM
#17788   Is there anything real about this company? idccwin 08/29/18 11:37:50 AM
#17787   How scam companies do it 236T568 08/29/18 10:21:09 AM
#17786   Hod nice open and good news all week. simmons420 08/29/18 09:47:09 AM
#17785   Paid promo goes through 9/13: https://m.facebook.com/groups/1793185850788994/ mayvid 08/22/18 02:56:49 PM
#17784   Paid promo ended Friday, FYI simon wagstaff 08/20/18 04:19:37 PM
#17783   Anything around 2 dollars is a steal for simmons420 08/20/18 02:03:46 PM
#17782   Play the bounce! This is a huge winner! MadHatter326 08/17/18 11:16:14 AM
#17781   Ouch! $1.95 and dropping! 236T568 08/16/18 02:03:28 PM
#17780   Yep, looks like it 236T568 08/16/18 01:48:52 AM
#17779   I confirmed a previous statement and made a simon wagstaff 08/15/18 12:51:51 PM
#17778   I like how you reply to your own mrcraigo 08/15/18 12:05:52 PM
#17777   Looks like it. here comes that drop you simon wagstaff 08/15/18 11:25:01 AM
#17776   Paid promotion period over again? simon wagstaff 08/14/18 11:18:06 AM
#17775   Still looking good here simmons420 08/14/18 11:12:38 AM
#17774   Hod nice move to start the week here. simmons420 08/13/18 10:43:30 AM
#17773   massive and Impressive... Plus a 52% Share Lock GemsBond 08/13/18 09:03:08 AM
#17772   WOW NICE! $GTBP made the list!!!! COOL GemsBond 08/13/18 08:53:14 AM
#17771   Good stuff....I'm long $GTBP https://seekingalpha.com/instablog/49359144-j-phil GunHawk 08/13/18 08:51:22 AM
#17770   Immuno Oncology is the Future of Cancer Treatment! MysticMonk 08/13/18 08:49:34 AM
#17769   Comments released by GT Pharma: "We believe these GunHawk 08/13/18 08:44:55 AM
#17768   $GTBP Technology! READ THIS: https://www.gtbiopharma.com/our-technologies MysticMonk 08/13/18 08:36:18 AM
#17767   well said!!! GT Biopharma, Inc. is a biotechnology GunHawk 08/13/18 08:15:28 AM
#17766   GTBP is one of 3 Biotech Stocks See GemsBond 08/13/18 08:12:28 AM
#17765   Immuno-oncology is the next big thing for big GemsBond 08/13/18 08:09:24 AM
#17764   $GTBP rebounding in the last week of trading. MysticMonk 08/13/18 07:46:43 AM
#17763   $GTBP closed up 5.96% last friday, on 1.11 GemsBond 08/13/18 07:45:16 AM
#17762   I have a feeling $GTBP is green today!!! GunHawk 08/13/18 07:43:35 AM
#17761   pre-market movers this morning. $GTBP is on my GemsBond 08/13/18 07:33:28 AM
#17760   good to see you GunHawk!!!!! MysticMonk 08/13/18 07:31:47 AM
#17759   Good morning $GTBP family!!!!! GunHawk 08/13/18 07:31:08 AM
#17758   $GTBP FIGHTS CANCER WITH IMMUNO ONCOLGY. IMMUNO ONCOLOGY FinanceAngel 08/13/18 06:25:57 AM
#17757   >>>>Most Common Forms of Cancer: Lung (1.69 million FinanceAngel 08/13/18 06:25:52 AM
#17756   Early stage testing has shown great promise. Working FinanceAngel 08/13/18 06:25:27 AM
#17755   Good morning BubbleGum! RevivalFire2018 08/13/18 06:24:52 AM
#17754   NEW HERE??-Be sure to check out their website: BubbleGum 08/13/18 06:24:10 AM
#17753   What other biotechnology company of this size do BubbleGum 08/13/18 06:23:50 AM
#17752   Right now investors seem to be favoring smaller BubbleGum 08/13/18 06:23:38 AM
#17751   Good morning everybody!!!! Good to see you all! BubbleGum 08/13/18 06:23:05 AM
PostSubject